Physician profile
Benjamin B Close
NPI 1730185802
$420,615.15
in general payments reported to CMS, 2019-2025
42 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $30K · 2021: $36K · 2022: $83K · 2023: $69K · 2024: $84K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Food and Beverage: $17K · Travel and Lodging: $13K · Consulting Fee: $5,936 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,748.54 |
| Food and Beverage | $16,962.03 |
| Travel and Lodging | $13,413.78 |
| Consulting Fee | $5,935.83 |
| Education | $154.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $206,622.80 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $62,834.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $57,174.90 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $41,510.26 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $16,904.09 | 2020-2025 | Tezspire |
| Genentech USA, INC. | $14,410.97 | 2019-2025 | Xolair |
| Csl Behring | $12,728.88 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $1,485.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,248.09 | 2020-2025 | |
| Grifols USA, LLC | $826.32 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $823.88 | 2020-2025 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $463.63 | 2021-2025 | Orladeyo |
| Leo Pharma INC. | $445.39 | 2021-2024 | Adbry |
| Pfizer INC. | $395.80 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $265.21 | 2023-2025 | Ryaltris |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Close listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.